This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
L

ASCO® 2024 Insights: "KIM-1 Biomarker Analysis in IMmotion010 - Adjuvant Atezo vs. Placebo in RCC Patients at Increased Risk of Recurrence After Resection"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Laurence Albiges
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Laurence Albiges
57 views
June 7, 2024

Chapters

Introduction to KIM-1 & IMmotion010 Study

00:00

Biomarker Identification & KIM-1 Significance

01:37

KIM-1 Levels & Disease-Free Survival Outcome

05:16

Atezolizumab Treatment & KIM-1 Predictive Value

06:46

Conclusions & Future Directions for KIM-1

07:50

0 Comments
Login to view comments. Click here to Login

2024 ASCO® Annual Meeting Insights Hub: GU Videos

21:54
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Prostate Cancer Take-Home Messages

Feat. E. Efstathiou
10:19
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implicat…

Feat. K. Mittal
15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
View All

Related Content

AUTOPLAY
Advanced Prostate Cancer Consensus Conference (APCCC)

APCCC 2026

Fri, Feb 27, 2026
International Urology Cancer Summit - IUCS

Second International Urology Cancer Summit

Fri, Sep 27, 2024
14:16
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…

Feat. E. Efstathiou
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
09:14
Robert Dreicer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

13:37
SIR 2023 Conference Coverage

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary
15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
03:05
Benjamin L. Maughan

Testosterone Suppression and Recovery in Patients With Advanced Pros…

10:19
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implicat…

Feat. K. Mittal
06:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence f…

Feat. J. Hafron
07:27
Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
09:45
Northwestern Medicine Oncology and Hematology

Differences Between Urologists and Medical Oncologists in the Manage…

Feat. W. Catalona
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin
06:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very…

Feat. M. Zarba
19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

13:46
David McDermott

Overview of a SoC in 1L mRCC Focusing on the Long-Term Survival Data